| Proposed Ticker: BSEN | 40 Ramland Road South, Suite 10 | |
| Exchange: NASDAQ-National Market | Orangeburg, New York 10962 | |
| Industry: Manufacturing | (914) 359-2250 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 9/20/96 | |
| U.S. Shares Filed: | 0 | Filing Price: | - | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $50,000,000 | |
| Primary Shares: | 0 | Expenses: | - | |
| Secondary Shares: | 0 | Shs Out After: | ||
| Manager | Tier | Phone |
| UBS Securities Inc. | Lead Manager | (212) 230-4000 |
| Montgomery Securities | Co-manager | 4156272220 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $0.20 | $2.85 | $0.00 | Assets: | $15.41 |
| Net Income: | -$7.76 | -$3.14 | -$1.77 | Liabilities: | $3.98 |
| EPS: | Equity: | $11.43 | |||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company has developed proprietary technology which enables physicians to accurately and safely navigate medical instruments within patients' bodies during the performance of a wide variety of minimally invasive medical procedures. The company's technology consists of miniature, disposable location sensors incorporated into catheters and other medical instruments, a reusable "location pad" which emits non-hazardous, low-level electromagnetic energy and a proprietary computer system that converts the raw data gathered into a user-friendly map and location guide. The company's products permit physicians to continuously acquire, display, compare, store and retrieve three dimensional spatially correct anatomical data and corresponding physiological data, which will provide physicians with important navigational and functional information not currently available during the performance of many medical procedures. The company believes that its proprietary technology will improve the accuracy and minimize the invasiveness of many diagnostic and therapeutic procedures, producing better clinical results. In addition, the company believes that its technology will increase safety, reduce patient recovery times and lower the overall costs associated with a wide variety of invasive medical procedures. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund research and development, clinical studies, sales and marketing efforts, acquisitions of capital equipment and for working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.